Fig. 1
From: MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling
MASTL expression is upregulated in colon cancer. Patients were evaluated by tumor stage and expression levels were compared to expression levels of normal adjacent samples. a 250 patients were analyzed from the VMC/MCC data set. Wilcoxon rank sum test was used to test for significance between each stage and normal (P < 0.001). b 315 patients were analyzed from the TCGA database. Kruskal- Wallis rank sum test was used to test for significance between each stage and normal (P < 0.001). Immunohistochemical analysis of (c) normal and colon cancer patients & (d) AOM/DSS and APCmin mice tumors for MASTL expression. e & f Comparison of overall survival and disease-specific survival in correlation with MASTL expression. Patients with high expression were defined as having greater than median expression of MASTL and were compared to the low expression group (less than the median expression value). Kaplan-Meier analysis was performed, comparing patients with high MASTL expression (red line) to low MASTL expression (blue line). Higher expression of MASTL correlated with significantly worse overall survival (P = 0.03, n = 250) (A) and a trend toward worse disease-specific survival (P = 0.05, n = 250)